enGene Reports Q3 2026 Financial Results
Company reveals Q3 results and BLA targeting datalimogene for urology; cash balance reported at $266 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day